Huakang Biomedical Holdings Company Limited (8622.HK)

HKD 0.36

(-1.39%)

Market Cap (In HKD)

177.66 Million

Revenue (In HKD)

24.62 Million

Net Income (In HKD)

-5.78 Million

Avg. Volume

547.33 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.08-0.247
PE
-35.5
EPS
-0.01
Beta Value
0.076
ISIN
KYG4644W1069
CUSIP
G4644W106
CIK
-
Shares
500472000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Chunguang Zhang
Employee Count
-
Website
https://www.huakangbiomedical.com
Ipo Date
2018-12-13
Details
Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; auxiliary reproductive supplies and equipment; and healthcare products and supplements under the Nutronic brand to customers, as well as through online and offline platforms and channels. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biomedical Holdings Company Limited was founded in 1992 and is headquartered in Wan Chai, Hong Kong.